Survival in heart failure
- Heart failure (HF) is an enormous public health burden with 300,000 new deaths each year and a prevalence of 6.5 million people in the United States1.
- There is large variability in HF prognosis2, and there is a need for a broader systemic approach to identify novel circulating markers of HF progression.
- One of the most robust and validated models for mortality prediction in HF patients is the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) Score3.
- Additionally, the use of N-Terminal pro-B-Type Natriuretic Peptide (NTproBNP) has been shown to be valuable in prognosis prediction4.
- It is uncertain if the plasma proteome is a better prediction tool for the course of HF compared to the clinical risk score MAGGIC and NTproBNP.
PosterUtility of proteomic trajectories of cardiovascular risk and cardiorespiratory fitness to monitor adverse health states throughout post-COVID-19 illness
Cardiovascular involvement is a prominent observation in patients during the acute phase of COVID-19 infection, as well as in convalescence. However, the etiology, trajectory, and underlying biology of cardiac dysfunction across the spectrum of COVID-19 illness is not fully understood. To address this, the CISCO-19 study (NCT04403607) was formed to investigate the multisystem effects of COVID-19 from hospitalized patients
PosterIdentifying genetic and environmental influences on proteins associated with age, cardiovascular risk, and other endpoints using the SomaScan® Assay
Protein quantitative trait locus pQTL studies identify genetic variants that are statistically associated with protein levels Results from the growing number of pQTL studies can be combined with genome wide association studies to identify proteins that underlie the genetic risk of disease, thus revealing the mechanisms of disease and potential drug targets.
PosterSomaScan® Platform confirmation and performance validation
The SomaScan® Platform for proteomic profiling uses 7288 (7K) SOMAmer® reagents, single stranded DNA aptamers, to 6596 unique Human Protein Targets. The modified aptamer binding reagents1, SomaScan assay2, its performance characteristic for 5k3 and 7k4 content sets, and specificity5,6,7 to human targets have been previously described. We combine profiles of validation and performance metrics with orthogonal confirmation of specificity from published literature to provide a comprehensive view of the specificity and utility of the SomaScan Platform.